Lineage closes $6M second tranche of registered direct offering; total $30M received

Lineage Cell Therapeutics, Inc.

Second tranche closed Jan 27, 2025; issued 7,894,737 common shares + warrants at $0.76/unit.
Warrants exercisable at $0.91/share from May 21, 2025; expire on OpRegen Phase 2/3 milestone or May 2028.
Potential additional $36M if all warrants exercised; $30M gross proceeds collected to date.
Broadwood Partners (affiliate of board member Neal Bradsher) purchased the second tranche shares.
Shareholders approved issuance at Jan 27 special meeting with 114.1M votes for, 6.7M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.